Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Positive Regulator Molecules02:39

Positive Regulator Molecules

6.4K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
6.4K
Positive Regulator Molecules01:45

Positive Regulator Molecules

133.6K
To consistently produce healthy cells, the cell cycle—the process that generates daughter cells—must be precisely regulated.
133.6K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

6.2K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.2K
Negative Regulator Molecules01:23

Negative Regulator Molecules

38.2K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.2K
Anaphase Promoting Complex00:50

Anaphase Promoting Complex

3.3K
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A progeria syndrome links DNA hypermethylation to age-related pathology.

Nature genetics·2026
Same author

Exosomal miR-4644 Targets SPRY3 to Promote Proliferation and Invasion of Pancreatic Cancer.

Cancer medicine·2026
Same author

Discovery of EGT710, an Oral Nonpeptidomimetic Reversible Covalent SARS-CoV-2 Main Protease Inhibitor.

Journal of medicinal chemistry·2026
Same author

Spontaneous inferior epigastric artery hemorrhage in a COVID-19 patient with membranous nephropathy on anticoagulant therapy: a Case Report.

Frontiers in medicine·2026
Same author

The current understanding of KRAS oligomerization on membranes.

Current opinion in structural biology·2025
Same author

Comprehensive treatment and surgical features of giant hepatic hemangioma with Kasabach-Merritt syndrome in an adult.

Hepatobiliary surgery and nutrition·2025

Related Experiment Video

Updated: Jan 6, 2026

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay
12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

19.3K

Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitor.

Yongqi Deng1, Gerald W Shipps1, Lianyun Zhao1

  • 1Merck Research Laboratories, 320 Bent Street, Cambridge, MA 02141, USA.

Bioorganic & Medicinal Chemistry Letters
|December 17, 2013
PubMed
Summary

Researchers discovered novel quinoline-based kinase inhibitors that disrupt cyclin-dependent kinase 2 (CDK2) interactions and act as ATP-competitive inhibitors. These compounds show high affinity for the inactive CDK2 monomer, offering a new therapeutic strategy.

Keywords:
CDK2High throughput screeningKinasesModulatorTumor

More Related Videos

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.7K
Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
09:39

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications

Published on: January 27, 2014

13.0K

Related Experiment Videos

Last Updated: Jan 6, 2026

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay
12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

19.3K
Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.7K
Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
09:39

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications

Published on: January 27, 2014

13.0K

Area of Science:

  • Medicinal Chemistry
  • Molecular Biology
  • Biochemistry

Background:

  • Cyclin-dependent kinase 2 (CDK2) plays a crucial role in cell cycle regulation.
  • Dysregulation of CDK2 activity is implicated in various diseases, including cancer.
  • Targeting protein-protein interactions of CDK2 presents a therapeutic opportunity.

Purpose of the Study:

  • To discover novel small molecules that inhibit CDK2.
  • To identify inhibitors that disrupt the CDK2/cyclin A interaction.
  • To develop ATP-competitive inhibitors with improved affinity.

Main Methods:

  • Screening of quinoline-based compounds using affinity-selection/mass spectrometry.
  • Secondary assays to identify selective inhibitors of the inactive CDK2 monomer.
  • Chemical modifications to optimize inhibitor affinity (Kd).

Main Results:

  • Discovery of a new class of quinoline-based kinase inhibitors.
  • Identification of compounds that disrupt CDK2/cyclin A interaction.
  • Achieved a significant improvement in binding affinity from 1 μM to 0.005 μM (Kd).

Conclusions:

  • Novel quinoline-based inhibitors effectively target CDK2.
  • These inhibitors disrupt essential CDK2 protein-protein interactions.
  • The developed compounds represent promising leads for therapeutic intervention.